CVR number 39880377
Industry 21.2000 Manufacture of pharmaceutical preparations

Beo Therapeutics ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
   
Loading...

Loading...

   
Loading...
Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  29.0% 21.1% 11.5% 19.8% 19.8%  
Credit score (0-100)  3 5 20 5 5  
Credit rating  B B BB B B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 0.0 0.0  
EBITDA  0.0 0.0 0.0 0.0 0.0  
EBIT  0.0 0.0 0.0 0.0 0.0  
Pre-tax profit (PTP)  0.0 0.0 0.0 0.0 0.0  
Net earnings  0.0 0.0 0.4 0.0 0.0  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 0.0 0.0  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 67.4 40.0 40.0 40.0  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 67.4 40.0 40.0 40.0  
Net Debt  0.0 -67.4 0.0 0.0 0.0  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 0.0 0.0  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 67 40 40 40  
Balance sheet change%  0.0% 0.0% -40.7% 0.0% 0.0%  
Added value  0.0 0.0 0.0 0.0 0.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 40 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 0.0 0.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 0.0% 0.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROI %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROE %  0.0% 0.0% 0.8% 0.0% 0.0%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 100.0% 100.0% 100.0% 100.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 0.0% 0.0%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 0.0 0.0  
Current Ratio  0.0 0.0 0.0 0.0 0.0  
Cash and cash equivalent  0.0 67.4 0.0 0.0 0.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 67.4 0.0 0.0 0.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0